95 related articles for article (PubMed ID: 12019164)
1. Increased tumorigenicity, but unchanged immunogenicity, of transporter for antigen presentation 1-deficient tumors.
Qin Z; Harders C; Cao X; Huber C; Blankenstein T; Seliger B
Cancer Res; 2002 May; 62(10):2856-60. PubMed ID: 12019164
[TBL] [Abstract][Full Text] [Related]
2. Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis.
Johnsen AK; Templeton DJ; Sy M; Harding CV
J Immunol; 1999 Oct; 163(8):4224-31. PubMed ID: 10510359
[TBL] [Abstract][Full Text] [Related]
3. Restoration of the expression of transporters associated with antigen processing in lung carcinoma increases tumor-specific immune responses and survival.
Lou Y; Vitalis TZ; Basha G; Cai B; Chen SS; Choi KB; Jeffries AP; Elliott WM; Atkins D; Seliger B; Jefferies WA
Cancer Res; 2005 Sep; 65(17):7926-33. PubMed ID: 16140964
[TBL] [Abstract][Full Text] [Related]
4. Restoration of the expression of transports associated with antigen processing in human malignant melanoma increases tumor-specific immunity.
Tao J; Li Y; Liu YQ; Wang L; Yang J; Dong J; Wu Y; Shen GX; Tu YT
J Invest Dermatol; 2008 Aug; 128(8):1991-6. PubMed ID: 18385764
[TBL] [Abstract][Full Text] [Related]
5. TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors.
Doorduijn EM; Sluijter M; Querido BJ; Oliveira CC; Achour A; Ossendorp F; van der Burg SH; van Hall T
J Clin Invest; 2016 Feb; 126(2):784-94. PubMed ID: 26784543
[TBL] [Abstract][Full Text] [Related]
6. Combining the antigen processing components TAP and Tapasin elicits enhanced tumor-free survival.
Lou Y; Basha G; Seipp RP; Cai B; Chen SS; Moise AR; Jeffries AP; Gopaul RS; Vitalis TZ; Jefferies WA
Clin Cancer Res; 2008 Mar; 14(5):1494-501. PubMed ID: 18316574
[TBL] [Abstract][Full Text] [Related]
7. The mutation in the ATP-binding region of JAK1, identified in human uterine leiomyosarcomas, results in defective interferon-gamma inducibility of TAP1 and LMP2.
Hayashi T; Kobayashi Y; Kohsaka S; Sano K
Oncogene; 2006 Jul; 25(29):4016-26. PubMed ID: 16474838
[TBL] [Abstract][Full Text] [Related]
8. Induction of immunogenicity of a human renal-cell carcinoma cell line by TAP1-gene transfer.
Kallfelz M; Jung D; Hilmes C; Knuth A; Jaeger E; Huber C; Seliger B
Int J Cancer; 1999 Mar; 81(1):125-33. PubMed ID: 10077163
[TBL] [Abstract][Full Text] [Related]
9. Effect of B7.1 costimulation on T-cell based immunity against TAP-negative cancer can be facilitated by TAP1 expression.
Li XL; Liu YY; Knight D; Odaka Y; Mathis JM; Shi R; Glass J; Zhang QJ
PLoS One; 2009 Jul; 4(7):e6385. PubMed ID: 19629186
[TBL] [Abstract][Full Text] [Related]
10. TAP expression reduces IL-10 expressing tumor infiltrating lymphocytes and restores immunosurveillance against melanoma.
Zhang QJ; Seipp RP; Chen SS; Vitalis TZ; Li XL; Choi KB; Jeffries A; Jefferies WA
Int J Cancer; 2007 May; 120(9):1935-41. PubMed ID: 17278102
[TBL] [Abstract][Full Text] [Related]
11. Systemic deficits in transporter for antigen presentation (TAP)-1 or proteasome subunit LMP2 have little or no effect on tumor incidence.
Johnsen AK; France J; Nagy N; Askew D; Abdul-Karim FW; Gerson SL; Sy MS; Harding CV
Int J Cancer; 2001 Feb; 91(3):366-72. PubMed ID: 11169961
[TBL] [Abstract][Full Text] [Related]
12. TAP1-deficient mice select a CD8+ T cell repertoire that displays both diversity and peptide specificity.
Sandberg JK; Chambers BJ; Van Kaer L; Kärre K; Ljunggren HG
Eur J Immunol; 1996 Feb; 26(2):288-93. PubMed ID: 8617293
[TBL] [Abstract][Full Text] [Related]
13. TAP expression provides a general method for improving the recognition of malignant cells in vivo.
Alimonti J; Zhang QJ; Gabathuler R; Reid G; Chen SS; Jefferies WA
Nat Biotechnol; 2000 May; 18(5):515-20. PubMed ID: 10802618
[TBL] [Abstract][Full Text] [Related]
14. Reduced expression of the transporter associated with antigen processing 1 molecule in malignant glioma cells, and its restoration by interferon-gamma and -beta.
Satoh E; Mabuchi T; Satoh H; Asahara T; Nukui H; Naganuma H
J Neurosurg; 2006 Feb; 104(2):264-71. PubMed ID: 16509500
[TBL] [Abstract][Full Text] [Related]
15. Autoreactivity to self H-2Kb peptides in TAP1 mice. Intravenous administration of H-2Kb class I-derived peptides induces long-term survival of grafts from C57BL/6 donors.
Marrero I; Benvenutti LA; Kalil J; Coelho V
Immunology; 2005 Aug; 115(4):484-94. PubMed ID: 16011517
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expressing IL-10.
Salazar-Onfray F; Charo J; Petersson M; Freland S; Noffz G; Qin Z; Blankenstein T; Ljunggren HG; Kiessling R
J Immunol; 1997 Oct; 159(7):3195-202. PubMed ID: 9317117
[TBL] [Abstract][Full Text] [Related]
17. MHC class I expression and CD8+ T cell development in TAP1/beta 2-microglobulin double mutant mice.
Ljunggren HG; Van Kaer L; Sabatine MS; Auchincloss H; Tonegawa S; Ploegh HL
Int Immunol; 1995 Jun; 7(6):975-84. PubMed ID: 7577806
[TBL] [Abstract][Full Text] [Related]
18. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway.
Seliger B; Ritz U; Abele R; Bock M; Tampé R; Sutter G; Drexler I; Huber C; Ferrone S
Cancer Res; 2001 Dec; 61(24):8647-50. PubMed ID: 11751378
[TBL] [Abstract][Full Text] [Related]
19. Furin-processed antigens targeted to the secretory route elicit functional TAP1-/-CD8+ T lymphocytes in vivo.
Medina F; Ramos M; Iborra S; de León P; Rodríguez-Castro M; Del Val M
J Immunol; 2009 Oct; 183(7):4639-47. PubMed ID: 19752221
[TBL] [Abstract][Full Text] [Related]
20. TAP1-/- mice present oligoclonal BV-BJ expansions following the rejection of grafts bearing self antigens.
Marrero I; Huffman D; Kalil J; Sercarz EE; Coelho V
Immunology; 2006 Aug; 118(4):461-71. PubMed ID: 16895555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
